Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|5.32583.0001||Glass bottle||10 mg||
|Overview||A diphenyl substituted imidazole based compound that directly and selectively targets TLR1/2 and induces their dimerization and activates TLR1 & 2 signaling leading to NF-κB and AP-1 activation (KD = 182 and 478 nM, respectively; EC50 = 52.9 nM for TLR2 in HEK-Blue cells over-expressing hTLR2). Does not affect the dimerization of TLR2/TLR6 and exhibits poor affinity towards TLR3, TLR4, TLR5, TLR7 and TLR8. Shown to compete with Pam3CSK4 (Cat. No. 506350; Ki = 45.4 nM) for binding to TLR1/2 interface and enhance heterodimerization. Up-regulates the expression of TLR1, TLR2, TNFα, IL-10, and iNOS in RAW 264.7 macrophages in a time-dependent manner. Shown to be non-toxic up to 100 µM concentration.
Please note that the molecular weight for this compound is batch-specific due to variable water content.
|References||Cheng, K., et al. 2014. Manuscript in preparation.|
|Purity||≥98% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
TLR1/TLR2 Agonist II, CU-T12-9 - Calbiochem SDS
|Cheng, K., et al. 2014. Manuscript in preparation.|
|NPI Flyer- Epigenetics and Nuclear Function Feature (EMD)|
|New Products - Antibodies, Small Molecule, Inhibitors|
|White Paper: Further considerations of antibody validation and usage. (EMD)|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.